In vivo studies in apolipoprotein E (apoE) knockout mice revealed that PCSK9 silencing could inhibit the progression of atherosclerosis by reducing vascular inflammation and limiting activation of the TLR4/NF-κB signaling pathway without changing plasma cholesterol levels (33). Here, NFKB1 is linked to atherosclerosis.